Starton Therapeutics says Keith Darragh has joined the company as its chief financial officer with immediate effect

0
8

Darragh is the former chief financial officer of Pharmacosmos Therapeutics Inc. and Eleison Pharmaceuticals LLC, where he led finance, administration, supply chain, and information technology and established the financial infrastructure to support clinical program advancement and product launch preparation

Starton Therapeutics Inc., a privately-owned, clinical-stage biotechnology powering continuous delivery of approved drugs for novel indications, announced that Keith Darragh has joined the company as its chief financial officer with immediate effect.

The company noted that Darragh is the former chief financial officer of Pharmacosmos Therapeutics Inc. and Eleison Pharmaceuticals LLC, where he led finance, administration, supply chain, and information technology and established the financial infrastructure to support clinical program advancement and product launch preparation.

He holds a Bachelor of Science in accounting (summa cum laude) and a Master of Business Administration from Montclair State University and is a certified public accountant (CPA) and chartered global management accountant (CGMA).

Darragh will oversee Starton’s finance department and lead all aspects of the company’s financial strategy and operations, including budgeting and planning, accounting, tax, and financial reporting.

In a statement, Pedro Lichtinger, Starton’s chief executive officer commented: “Our experienced team is further solidified with Keith’s addition. Keith has substantial financial and operational expertise and his extensive experience as CFO and senior-level finance executive of publicly traded companies will provide us with the leadership needed as we advance towards a public listing.”

Darragh is taking over from Christopher Chipman, who served as Starton’s consulting chief financial officer from January 2018 through July 2020.

“The Board of Directors would like to thank Chris for his service to the Company and wishes him all the best in his future endeavours,” Lichtinger added.

Starton Therapeutics is a clinical-stage biotechnology company focused on transforming standard of care therapeutics. It uses proven continuous delivery technology with proprietary drivers to obtain new indications or develop on-label superiority for patients with hematological malignancies.

The above has been published by Proactive Investors Limited (the « Company ») on its website and is made available subject to the terms and conditions of use of its website (see T&C ).

Starton Therapeutics CEO Pedro Lichtinger presents to investors at Proactive’s One2One Investor Forum. The privately-held New York based group uses transdermal technology with proprietary drivers to obtain new indications or develop on-label superiority for patients with hematological…

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use.


SOURCE: https://www.w24news.com

Donnez votre point de vue et aboonez-vous!

Votre point de vue compte, donnez votre avis

[maxbutton id= »1″]